Summit Therapeutics prices at-the-market offering of up to 25.8M shares at $14.74/share

Filed July 23, 2026 · ~2 min read

Key Changes

• high

  Summit Therapeutics is conducting an at-the-market offering of up to 25,780,189 shares (last sale $14.74 per share) for gross proceeds of up to $380M. Shares will be sold from time to time at varying market prices via Distribution Agreement with Sales Agent.

  The Offering verify on EDGAR →
• high

  Implied post-offering market capitalization of $12.1B based on offer price of $14.74 and 818,900,551 shares outstanding after the offering.

  The Offering verify on EDGAR →
• high

  Proceeds will fund development of lead candidate ivonescimab, including clinical trials in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and other solid tumors, plus working capital and general corporate purposes.

  Use of Proceeds verify on EDGAR →